Holen Sie sich die Stockscreener-App
8.31
13.06%
0.96
Handel nachbörslich:
8.21
-0.10
-1.20%
Schlusskurs vom Vortag:
$7.35
Offen:
$7.4
24-Stunden-Volumen:
2.05M
Relative Volume:
1.62
Marktkapitalisierung:
$340.01M
Einnahmen:
$128.29M
Nettoeinkommen (Verlust:
$-30.69M
KGV:
-10.13
EPS:
-0.82
Netto-Cashflow:
$-27.17M
1W Leistung:
+10.07%
1M Leistung:
+3.88%
6M Leistung:
-73.93%
1J Leistung:
-83.59%
1-Tages-Spanne:
$7.31
$8.49
1-Wochen-Bereich:
$6.62
$8.49
52-Wochen-Spanne:
$6.32
$58.23
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Vergleichen Sie RXST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
8.31 | 300.73M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
RXSIGHT STOCK: Lose Money on Your RxSight, Inc. - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming DeadlinesRXST - FinancialContent
RxSight’s Earnings Call: Mixed Results Amid Growth and Challenges - MSN
RxSight, Inc. (NASDAQ:RXST) Q2 2025 Earnings Call Transcript - MSN
RXST INVESTOR NOTICE: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - Morningstar
Shareholders of RxSight, Inc. (RXST): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages RxSight, Inc. - GlobeNewswire
Lost Money on RxSight, Inc. (RXST)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Class Action Lawsuit Filed: RxSight, Inc. (RXST)Join by September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
RXST COURT NOTICE: RxSight, Inc. Investors may have been - GlobeNewswire
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that RxSight, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RxSight, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsRXST - PR Newswire
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd - PR Newswire
Class Action Lawsuit Filed Against RxSight, Inc. (RXST)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
RxSight, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsRXST - 富途牛牛
Needham & Company LLC Cuts RxSight (NASDAQ:RXST) Price Target to $11.00 - Defense World
Investor Alert: Deadline Approaching to Join RxSight, Inc. (RXST) Class ActionContact Levi & Korsinsky - ACCESS Newswire
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that RxSight, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is RxSight Inc. building a consolidation baseFree Buy Low Sell High Stock Watch - Newser
Should you hold or exit RxSight Inc. nowStable Swing Setup with Safety Analysis - Newser
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi Reminds RxSight Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025RXST - Morningstar
RXST NEWS: Did RxSight, Inc. Mislead Investors? Contact BFA - GlobeNewswire
Automated trading signals detected on RxSight Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
RxSight's Strategic Reinvention: Can International Expansion and Product Innovation Justify a Re-Rating? - AInvest
Class Action Filed Against RxSight, Inc. (RXST) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Investors in RxSight, Inc. (RXST): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages RxSight, Inc. - GlobeNewswire
UBS Adjusts RxSight Price Target to $8 From $16, Maintains Neutral Rating - MarketScreener
RxSight stock price target cut by UBS to $8 on weak LDD placements - Investing.com
RxSight Inc. (RXST) PT Lowered to $8 at UBS - StreetInsider
Earnings call transcript: Rxsight Q2 2025 reports wider loss, stock rises - Investing.com
RXST SHAREHOLDERS: RxSight, Inc. Stock Drop Triggers - GlobeNewswire
RxSight, Inc. Reports Q2 2025 Financial Results - TipRanks
RxSight’s Revenue Slips As Losses Grow But Margins Hold Steady - Finimize
RxSight, Inc. Presents Second Quarter 2025 Revenue, Reiterates Full-Year Guidance - VisionMonday.com
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Rxsight earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
RxSight, Inc. (RXST) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Investors in RxSight, Inc. Should Contact The Gross Law - GlobeNewswire
RxSight, Inc. Reports Second Quarter 2025 Financial Results - The Manila Times
RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before September 22, 2025RxSight, Inc. (RXST) - ACCESS Newswire
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39% - simplywall.st
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):